Reincarnation of ancient links between coagulation and complement

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S121-S132

  Conway, E M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Endothelial cells; Innate immunity; Platelet; Thrombosis; Thrombotic microangiopathy

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 9A; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C2A; COMPLEMENT COMPONENT C2B; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C6; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; KININOGEN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 1; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 3; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR; COMPLEMENT;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; BINDING AFFINITY; BLOOD CLOTTING; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT FIXATION; COMPLEMENT SYSTEM; CROSS REACTION; CYTOKINE RELEASE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; THROMBOCYTE ACTIVATION; ANIMAL; CELL COMMUNICATION; EVOLUTION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL EVOLUTION; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CELL COMMUNICATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION;

EID: 84931329600     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12950     Document Type: Review

References (119)

1. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002; 27: 67-74.
2. Dodds AW. Which came first, the lectin/classical pathway or the alternative pathway of complement? Immunobiology 2002; 205: 340-54.
3. Iwanaga S. The molecular basis of innate immunity in the horseshoe crab. Curr Opin Immunol 2002; 14: 87-95.
4. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-6.
5. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-43.
6. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25: 1265-75.
7. Wijeyewickrema LC, Yongqing T, Tran TP, Thompson PE, Viljoen JE, Coetzer TH, Duncan RC, Kass I, Buckle AM, Pike RN. Molecular determinants of the substrate specificity of the complement-initiating protease, C1r. J Biol Chem 2013; 288: 15571-80.
8. Degn SE, Jensen L, Hansen AG, Duman D, Tekin M, Jensenius JC, Thiel S. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol 2012; 189: 3957-69.
9. Dobo J, Schroeder V, Jenny L, Cervenak L, Zavodszky P, Gal P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol 2014; 61: 69-78.
10. Lachmann PJ, Hughes-Jones NC. Initiation of complement activation. Springer Semin Immunopathol 1984; 7: 143-62.
11. Nilsson B, Ekdahl KN. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 2012; 217: 1106-10.
12. Saggu G, Cortes C, Emch HN, Ramirez G, Worth RG, Ferreira VP. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 2013; 190: 6457-67.
13. Langer F, Spath B, Fischer C, Stolz M, Ayuk FA, Kroger N, Bokemeyer C, Ruf W. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood 2013; 121: 2324-35.
14. Pike RN, Wijeyewickrema LC. The molecular switches controlling the interaction between complement proteases of the classical and lectin pathways and their substrates. Curr Opin Struct Biol 2013; 23: 820-7.
15. Parej K, Dobo J, Zavodszky P, Gal P. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while alpha2-macroglobulin is not. Mol Immunol 2013; 54: 415-22.
16. Harold FM. Inorganic polyphosphates in biology: structure, metabolism, and function. Bacteriol Rev 1966; 30: 772-94.
17. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-56.
18. Montilla M, Hernandez-Ruiz L, Garcia-Cozar FJ, Alvarez-Laderas I, Rodriguez-Martorell J, Ruiz A. Polyphosphate binds to human von Willebrand factor in vivo and modulates its interaction with Glycoprotein Ib. J Thromb Haemost 2012; 10: 2315-23.
19. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-8.
20. Mutch NJ, Myles T, Leung LL, Morrissey JH. Polyphosphate binds with high affinity to exosite II of thrombin. J Thromb Haemost 2010; 8: 548-55.
21. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-8.
22. Wat J, Foley JH, Krisinger MJ, Ocariza LM, Lei V, Wasney G, Lameignere E, Strynadka NC, Smith SA, Morrissey JH, Conway EM. Polyphosphate suppresses complement via the terminal pathway. Blood 2014; 123: 768-76.
23. Zhang Q, Li Y, Tang CM. The role of the exopolyphosphatase PPX in avoidance by Neisseria meningitidis of complement-mediated killing. J Biol Chem 2010; 285: 34259-68.
24. Keizer MP, Pouw RB, Kamp AM, Patiwael S, Marsman G, Hart MH, Zeerleder S, Kuijpers TW, Wouters D. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2. Eur J Immunol 2015; 45: 544-50.
25. Pavlov VI, Skjoedt MO, Siow Tan Y, Rosbjerg A, Garred P, Stahl GL. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012; 126: 2227-35.
26. Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009; 114: 4538-45.
27. Ekdahl KN, Nilsson B. Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b. J Immunol 1995; 154: 6502-10.
28. Nilsson-Ekdahl K, Nilsson B. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1. Eur J Immunol 2001; 31: 1047-54.
29. Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, Uhrin D, Barlow PN, Pangburn MK, Kavanagh D. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009; 182: 7009-18.
30. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez de Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007; 28: 222-34.
31. Buraczynska M, Ksiazek P, Zukowski P, Benedyk-Lorens E, Orlowska-Kowalik G. Complement factor H gene polymorphism and risk of cardiovascular dnase in end-stage renal disease patients. Clin Immunol 2009; 132: 285-90.
32. Tsai HM. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev 2014; 28: 187-97.
33. Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014; 36: 399-420.
34. Feng S, Liang X, Cruz MA, Vu H, Zhou Z, Pemmaraju N, Dong JF, Kroll MH, Afshar-Kharghan V. The interaction between factor H and von Willebrand factor. PLoS One 2013; 8: e73715.
35. Rayes J, Roumenina LT, Dimitrov JD, Repesse Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Fremeaux-Bacchi V, Lacroix-Desmazes S. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014; 123: 121-5.
36. Nolasco L, Nolasco J, Feng S, Afshar-Kharghan V, Moake J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers-brief report. Arterioscler Thromb Vasc Biol 2013; 33: 2524-8.
37. Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 2014; 40: 544-50.
38. van de Wouwer M, Conway EM. Novel functions of thrombomodulin in inflammation. Crit Care Med 2004; 32: S254-61.
39. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-57.
40. Zoja C, Locatelli M, Pagani C, Corna D, Isermann B, Remuzzi G, Conway EM, Noris M. Lack of the lectin-like domain of thrombomodulin worsens shiga toxin-associated HUS in mice. J Immunol 2012; 189: 3661-8.
41. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR. Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 1999; 36: 261-8.
42. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol 2006; 118: 127-36.
43. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007; 137: 181-92.
44. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172: 3869-75.
45. Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull 2006; 77-78: 5-22.
46. Ninomiya H, Sims PJ. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9. J Biol Chem 1992; 267: 13675-80.
47. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol 2013; 735: 155-72.
48. Falgarone G, Chiocchia G. Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res 2009; 104: 139-70.
49. Podack ER, Kolb WP, Muller-Eberhard HJ. The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol 1977; 119: 2024-9.
50. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
51. Bellac CL, Dufour A, Krisinger MJ, Loonchanta A, Starr AE, Auf dem Keller U, Lange PF, Goebeler V, Kappelhoff R, Butler GS, Burtnick LD, Conway EM, Roberts CR, Overall CM. Macrophage matrix metalloproteinase-12 dampens inflammation and neutrophil influx in arthritis. Cell Rep 2014; 9: 618-32.
52. Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 910-9.
53. Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, Shore A, Hess K, Ajjan R, Pease RJ, Keen JN, Standeven KF, Carter AM. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. DiabVasc Dis Res 2012; 9: 216-25.
54. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004; 30: 73-80.
55. Gushiken FC, Han H, Li J, Rumbaut RE, Afshar-Kharghan V. Abnormal platelet function in C3-deficient mice. J Thromb Haemost 2009; 7: 865-70.
56. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MW, Price JF, Smith KA, Grant PJ, Ajjan RA. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012; 55: 1103-13.
57. Millien VO, Lu W, Mak G, Yuan X, Knight JM, Porter P, Kheradmand F, Corry DB. Airway fibrinogenolysis and the initiation of allergic inflammation. Ann Am Thorac Soc 2014; 11(Suppl. 5): S277-83.
58. Owczarek D, Cibor D, Salapa K, Glowacki MK, Mach T, Undas A. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism. Inflamm Bowel Dis 2013; 19: 2616-24.
59. Bhole D, Stahl GL. Molecular basis for complement component 6 (C6) deficiency in rats and mice. Immunobiology 2004; 209: 559-68.
60. Ota H, Fox-Talbot K, Hu W, Qian Z, Sanfilippo F, Hruban RH, Baldwin WM 3rd. Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts. Transplantation 2005; 79: 276-81.
61. Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147: 1713-26.
62. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12: 682-7.
63. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185: 5628-36.
64. Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981; 153: 1391-404.
65. Krisinger MJ, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial EL, Conway EM. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120: 1717-25.
66. Dankert JR, Esser AF. Complement-mediated killing of Escherichia coli: dissipation of membrane potential by a C9-derived peptide. Biochemistry 1986; 25: 1094-100.
67. Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012; 287: 18831-42.
68. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114-7.
69. Huber-Lang M, Denk S, Fulda S, Erler E, Kalbitz M, Weckbach S, Schneider EM, Weiss M, Kanse SM, Perl M. Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro. Mol Immunol 2012; 50: 60-5.
70. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3: 249-77.
71. Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One 2013; 8: e59372.
72. Feng S, Liang X, Kroll MH, Chung DW, Afshar-Kharghan V. von Willebrand factor is a cofactor in complement regulation. Blood 2015; 125: 1034-7.
73. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-33.
74. Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, Remuzzi G. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443-52.
75. Reti M, Farkas P, Csuka D, Razso K, Schlammadinger A, Udvardy ML, Madach K, Domjan G, Bereczki C, Reusz GS, Szabo AJ, Prohaszka Z. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791-8.
76. Wu TC, Yang S, Haven S, Holers VM, Lundberg AS, Wu H, Cataland SR. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11: 1925-7.
77. Tati R, Kristoffersson AC, Stahl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013; 191: 2184-93.
78. Feng S, Eyler SJ, Zhang Y, Maga T, Nester CM, Kroll MH, Smith RJ, Afshar-Kharghan V. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 2013; 122: 1487-93.
79. Megyeri M, Jani PK, Kajdacsi E, Dobo J, Schwaner E, Major B, Rigo J Jr, Zavodszky P, Thiel S, Cervenak L, Gal P. Serum MASP-1 in complex with MBL activates endothelial cells. Mol Immunol 2014; 59: 39-45.
80. Jani PK, Kajdacsi E, Megyeri M, Dobo J, Doleschall Z, Futosi K, Timar CI, Mocsai A, Mako V, Gal P, Cervenak L. MASP-1 induces a unique cytokine pattern in endothelial cells: a novel link between complement system and neutrophil granulocytes. PLoS One 2014; 9: e87104.
81. Jenny L, Dobo J, Gal P, Schroeder V. MASP-1 of the complement system promotes clotting via prothrombin activation. Mol Immunol 2015; 65: 398-405.
82. Pagowska-Klimek I, Cedzynski M. Mannan-binding lectin in cardiovascular disease. Biomed Res Int 2014; 2014: 616817.
83. La Bonte LR, Pavlov VI, Tan YS, Takahashi K, Takahashi M, Banda NK, Zou C, Fujita T, Stahl GL. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 2012; 188: 885-91.
84. Frauenknecht V, Thiel S, Storm L, Meier N, Arnold M, Schmid JP, Saner H, Schroeder V. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin Exp Immunol 2013; 173: 112-20.
85. Schmaier AH. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol 2008; 8: 161-5.
86. DiScipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982; 45: 587-95.
87. Saito A. Plasma kallikrein is activated on dermatan sulfate and cleaves factor H. Biochem Biophys Res Commun 2008; 370: 646-50.
88. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71: 1450-6.
89. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renne T, Morrissey JH, Gruber A, Gailani D. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-46.
90. Torzewski M, Bhakdi S. Complement and atherosclerosis-united to the point of no return? Clin Biochem 2013; 46: 20-5.
91. Huang J, Huffman JE, Yamkauchi M, Trompet S, Asselbergs FW, Sabater-Lleal M, Tregouet DA, Chen WM, Smith NL, Kleber ME, Shin SY, Becker DM, Tang W, Dehghan A, Johnson AD, Truong V, Folkersen L, Yang Q, Oudot-Mellkah T, Buckley BM, et al. Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. Arterioscler Thromb Vasc Biol 2014; 34: 1093-101.
92. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M. Interaction between the coagulation and complement system. Adv Exp Med Biol 2008; 632: 71-9.
93. Foley JH, Peterson EA, Lei V, Wan LW, Krisinger MJ, Conway EM. Interplay between fibrinolysis and complement: plasmin cleavage of iC3b modulates immune responses. J Thromb Haemost 2015; 13 (Suppl. 1): S610-S8.
94. Carroll MC. Complement and humoral immunity. Vaccine 2008; 26(Suppl. 8): I28-33.
95. Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014; 25: 55-64.
96. Patzelt J, Mueller KA, Breuning S, Karathanos A, Schleicher R, Seizer P, Gawaz M, Langer HF, Geisler T. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis 2015; 238: 289-95.
97. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 2010; 184: 2686-92.
98. Martel C, Cointe S, Maurice P, Matar S, Ghitescu M, Theroux P, Bonnefoy A. Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS One 2011; 6: e18812.
99. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-9.
100. Okayama M, Oguri K, Fujiwara Y, Nakanishi H, Yonekura H, Kondo T, Ui N. Purification and characterization of human platelet proteoglycan. Biochem J 1986; 233: 73-81.
101. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambris JD, Nilsson B. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6: 1413-21.
102. Nayak A, Ferluga J, Tsolaki AG, Kishore U. The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunol Lett 2010; 131: 139-50.
103. Skoglund C, Wettero J, Tengvall P, Bengtsson T. C1q induces a rapid up-regulation of P-selectin and modulates collagen- and collagen-related peptide-triggered activation in human platelets. Immunobiology 2010; 215: 987-95.
104. Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, Ekdahl KN. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One 2010; 5: e12889.
105. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 2012; 34: 151-65.
106. Bosmann M, Grailer JJ, Ruemmler R, Russkamp NF, Zetoune FS, Sarma JV, Standiford TJ, Ward PA. Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. FASEB J 2013; 27: 5010-21.
107. Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus 2008; 17: 931-6.
108. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177: 4794-802.
109. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-14.
110. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 1986; 68: 875-80.
111. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
112. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053-60.
113. Ando B, Wiedmer T, Hamilton KK, Sims PJ. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 1988; 263: 11907-14.
114. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19: 225-33.
115. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170-5.
116. Dixon RH, Rosse WF. Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets. J Clin Invest 1977; 59: 360-8.
117. Polley MJ, Nachman RL. Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex. J Exp Med 1979; 150: 633-45.
118. Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol 2013; 735: 1-22.
119. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013; 190: 3839-47.